Prophylactic effects of an N- and L-type Ca2+ antagonist, cilnidipine, against cardiac hypertrophy and dysfunction in stroke-prone, spontaneously hypertensive rats

Canadian Journal of Physiology and Pharmacology

Volumn 83, Issue 8-9, 2005, Pages 785-790

  Takemori, Kumiko ^a   Ishida, Hiroyuki ^a   Dote, Kensaku ^a   Yamamoto, Kazuo ^a   Ito, Hiroyuki ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Ca2+ blocker; Cardiac hypertrophy; Growth factor; Hypertension

Indexed keywords

CALCIUM ANTAGONIST; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL N TYPE; CALCIUM ION; CAPTOPRIL; CILNIDIPINE; COLLAGEN TYPE 3; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBROBLAST GROWTH FACTOR; MYOSIN HEAVY CHAIN ALPHA; MYOSIN HEAVY CHAIN BETA; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CALCIUM TRANSPORT; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; GENE EXPRESSION; GENE EXPRESSION REGULATION; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; MALE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN EXPRESSION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPONTANEOUSLY HYPERTENSIVE RAT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CALCIUM CHANNEL BLOCKERS; CAPTOPRIL; CARDIOMEGALY; CEREBROVASCULAR ACCIDENT; COLLAGEN TYPE III; DIHYDROPYRIDINES; FIBROBLAST GROWTH FACTOR 2; HYPERTENSION; MALE; MYOCARDIUM; RATS; RATS, INBRED SHR; RATS, INBRED WKY; TRANSFORMING GROWTH FACTOR BETA; VENTRICULAR MYOSINS; VENTRICULAR REMODELING;

EID: 28944437692     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y05-067     Document Type: Article

References (26)

1. Bauersachs, J., Galuppo, P., Fraccarollo, D., Christ, M., and Ertl, G. 2001. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation, 104: 982-985.
2. Brooks, W.W., Bing, O.H., Conrad, C.H., O'Neill, L., Crow, M.T., Lakatta, E.G., et al. 1997. Captopril modifies gene expression in hypertrophied and failing hearts of aged spontaneously hypertensive rats. Hypertension, 30: 1362-1368.
3. Brooks, W.W., Bing, O.H., Boluyt, M.O., Malhotra, A., Morgan, J.P., Satoh, N., et al. 2000. Altered inotropic responsiveness and gene expression of hypertrophied myocardium with captopril. Hypertension, 35: 1203-1209.
4. Compagno, V., Di Liegro, I., Cestelli, A., and Donatelli, M. 2001. Effect of aging and hypertension on beta-myosin heavy chain in heart of spontaneously hypertensive rats. Int. J. Mol. Med. 7: 507-508.
5. Dalton, G.R., Jones, J.V., Levi, A.J., and Levy, A. 2000. Changes in contractile protein gene expression with ageing and with captopril-induced regression of hypertrophy in the spontaneously hypertensive rats. J. Hypertens. 18: 1297-1306.
6. Godfraind, T. 1994. Calcium antagonist and vasodilatation. Pharmacol. Ther. 64: 37-75.
7. 2+-sensitive PKC-dependent tyrosine kinase pathway. Acta Physiol. Scand. 168: 301-309.
8. Kim, S., Ohta, K., Hamaguchi, A., Yukimura, T., Miura, K., and Iwao, H. 2000. Effects of an AT1 receptor antagonist, an ACE inhibitor and a calcium channel antagonist on cardiac gene expression in hypertensive rats. Br. J. Pharmacol. 118: 549-556.
9. Krenz, M., and Robbins, J. 2004. Impact of beta-myosin heavy chain expression on cardiac function during stress. J. Am. Coll. Cardiol. 44: 2390-2397.
10. Kuwahara, F., Kai, H., Tokuda, K., Takeya, M., Takeshita, A., Egashira, K., and Imaizumi, T. 2004. Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation? Hypertension, 43: 739-745.
11. Lee, M.A., Bohm, M., Kim, S., Bachmann, S., Bachmann, J., Barder, M., and Ganten, D. 1995. Differential gene expression of renin and angiotensinogen in the TGR(mREN-2)27 transgenic rat. Hypertension, 25(4 Pt. 1): 570-580.
12. 2+ activated tension development in single adult cardiac myocytes. Circ. Res. 84: 1310-1317.
13. 2+ channels. Trends Pharmacol. Sci. 22: 526-532.
14. Ohta, K., Kim, S., Wanibuchi, H., Ganten, D., and Iwao, H. 1996. Contribution of local renin-angiotensin system to cardiac hypertrophy, phenotypic modulation, and remodeling in TGR(mRen2)27 transgenic rats. Circulation, 15: 785-791.
15. Petrich, B.G., and Wang, Y. 2004. Stress-activated MAP kinases in cardiac remodeling and heart failure; new insights from transgenic studies. Trends Cardiovasc. Med. 14: 50-55.
16. Raizada, V., Pathak, D., Skipper, B., Nakouzi, A., and Malhotra, A. 1999. Age-related difference in cardiac adaptation to chronic hypertension in rats, with and without nifedipine treatment. Mol. Cell Biochem. 198: 109-112.
17. Rosenkranz, S. 2004. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc. Res. 63: 423-432.
18. Schultz, Jel J., Witt, S.A., Glascock, B.J., Nieman, M.L., Reiser, P.J., Nix, S.L., et al. 2002. TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J. Clin. Investig. 109: 787-796.
19. 2+ channel. Circ. Res. 90: 174-181.
20. 2+ channel blocker cilnidipine in rats. Eur. J. Pharmacol. 434: 43-47.
21. Takami, T., and Shigematsu, M. 2003. Effects of calcium channel antagonists on left ventricular hypetrophy and diastolic function in patients with essential hypertension. Clin. Exp. Hypertens. 25: 525-535.
22. Takemori, K., Ito, H., and Suzuki, T. 2000. Effects of the AT1 receptor antagonist on adhesion molecule expression in leukocytes and brain microvessels of stroke-prone spontaneously hypertensive rats. Am. J. Hypertens. 13: 1233-1241.
23. Tokuda, K., Kai, H., Kuwahara, F., and Imaizumi, T. 2003. Sub-depressor dose of angiotensin type-1 receptor blocker inhibits transforming growth factor-beta-mediated perivascular fibrosis in hypertensive rat hearts. J. Cardiovasc. Pharmacol. 42(Suppl. 1): S61-S65.
24. Tokuda, K., Kai, H., Kuwahara, F., Yasukawa, H., Tahara, N., Kudo, H., Takemiya, K., Koga, M., Yamamoto, T., and Imaizumi, T. 2004. Pressure-independent effects of angiotensin II on hypertensive myocardial fibrosis. Hypertension, 43: 499-503.
25. Ueyama, H., Uchida, H., Konda, T., and Yoshimoto, R. 1999. Cilnidipine: preclinical profile and clinical evaluation. Cardiovasc. Drug Rev. 17: 341-357.
26. Varagic, J., Susic, D., and Frohlich, E.D. 2002. Cilnidipine improves spontaneously hypertensive rat coronary hemodynamics without altering cardiovascular mass and collagen. J. Hypertens. 20: 317-322.